RS55421B1 - Virusna partikula sa fuzionim proteinom, oslobođena nakon infekcije sisarskih ćelija humanim citomegalovirusom (hcmv) i njena primena - Google Patents

Virusna partikula sa fuzionim proteinom, oslobođena nakon infekcije sisarskih ćelija humanim citomegalovirusom (hcmv) i njena primena

Info

Publication number
RS55421B1
RS55421B1 RS20161007A RSP20161007A RS55421B1 RS 55421 B1 RS55421 B1 RS 55421B1 RS 20161007 A RS20161007 A RS 20161007A RS P20161007 A RSP20161007 A RS P20161007A RS 55421 B1 RS55421 B1 RS 55421B1
Authority
RS
Serbia
Prior art keywords
hcmv
infection
fusion protein
mammalian cells
viral particle
Prior art date
Application number
RS20161007A
Other languages
English (en)
Inventor
Sabine Becke
Sabine Reyda
Bodo Plachter
Original Assignee
Vakzine Projekt Man Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Man Gmbh filed Critical Vakzine Projekt Man Gmbh
Publication of RS55421B1 publication Critical patent/RS55421B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161Methods of inactivation or attenuation
    • C12N2710/16162Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20161007A 2010-04-06 2011-04-06 Virusna partikula sa fuzionim proteinom, oslobođena nakon infekcije sisarskih ćelija humanim citomegalovirusom (hcmv) i njena primena RS55421B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10003712 2010-04-06
EP11713689.5A EP2556150B1 (en) 2010-04-06 2011-04-06 Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
PCT/EP2011/001712 WO2011124371A1 (en) 2010-04-06 2011-04-06 Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof

Publications (1)

Publication Number Publication Date
RS55421B1 true RS55421B1 (sr) 2017-04-28

Family

ID=43923731

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20161007A RS55421B1 (sr) 2010-04-06 2011-04-06 Virusna partikula sa fuzionim proteinom, oslobođena nakon infekcije sisarskih ćelija humanim citomegalovirusom (hcmv) i njena primena

Country Status (25)

Country Link
US (1) US9486517B2 (sr)
EP (1) EP2556150B1 (sr)
JP (1) JP5827312B2 (sr)
KR (2) KR20170108167A (sr)
CN (1) CN102933706B (sr)
AU (1) AU2011238085B2 (sr)
BR (1) BR112012025392B1 (sr)
CA (1) CA2795346C (sr)
CY (1) CY1118138T1 (sr)
DK (1) DK2556150T3 (sr)
ES (1) ES2601850T3 (sr)
HR (1) HRP20161556T1 (sr)
HU (1) HUE030704T2 (sr)
IL (1) IL222229A (sr)
LT (1) LT2556150T (sr)
MX (1) MX2012011639A (sr)
MY (1) MY162335A (sr)
PL (1) PL2556150T3 (sr)
PT (1) PT2556150T (sr)
RS (1) RS55421B1 (sr)
RU (1) RU2623172C2 (sr)
SG (2) SG10201502271RA (sr)
SI (1) SI2556150T1 (sr)
SM (1) SMT201700002B (sr)
WO (1) WO2011124371A1 (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011101446A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
CA3094216A1 (en) 2018-06-08 2019-12-12 Vakzine Projekt Management Gmbh Viral particle - based vaccine
EP3587566A1 (en) 2018-06-29 2020-01-01 Bodo Plachter Hcmv vaccine strain
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白B(gB)多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733540A (en) * 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
DE19910044A1 (de) * 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
EP1799255A4 (en) * 2004-06-25 2008-10-01 Medimmune Vaccines Inc RECOMBINANT HUMANESE CYTOMEGALOVIRUS AND HETEROLOGIST ANTIGENS CONTAINING VACCINES

Also Published As

Publication number Publication date
CA2795346A1 (en) 2011-10-13
SG10201502271RA (en) 2015-05-28
EP2556150A1 (en) 2013-02-13
MY162335A (en) 2017-06-15
KR20170108167A (ko) 2017-09-26
AU2011238085A1 (en) 2012-10-18
RU2012146775A (ru) 2014-05-20
KR20130055586A (ko) 2013-05-28
IL222229A (en) 2017-08-31
JP2013529065A (ja) 2013-07-18
ES2601850T3 (es) 2017-02-16
BR112012025392B1 (pt) 2021-05-25
SG184261A1 (en) 2012-10-30
JP5827312B2 (ja) 2015-12-02
IL222229A0 (en) 2012-12-31
US20130202708A1 (en) 2013-08-08
PT2556150T (pt) 2016-11-04
HRP20161556T1 (hr) 2016-12-30
BR112012025392A2 (pt) 2015-09-22
HUE030704T2 (en) 2017-05-29
LT2556150T (lt) 2016-12-12
AU2011238085B2 (en) 2016-08-04
SMT201700002B (it) 2017-03-08
DK2556150T3 (en) 2016-12-05
PL2556150T3 (pl) 2017-05-31
KR101839535B1 (ko) 2018-04-27
CN102933706B (zh) 2016-01-13
CY1118138T1 (el) 2017-06-28
US9486517B2 (en) 2016-11-08
RU2623172C2 (ru) 2017-06-22
CN102933706A (zh) 2013-02-13
SI2556150T1 (sl) 2016-12-30
MX2012011639A (es) 2012-11-29
WO2011124371A1 (en) 2011-10-13
CA2795346C (en) 2022-05-03
EP2556150B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
IL222229A0 (en) Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
IL287381A (en) Pharmaceutical preparations of human rpe cells and their use
HRP20182194T1 (hr) Onkolitički herpes simpleks virus i njegova terapeutska uporaba
IL251338B (en) Plant cells and extracts containing virus-like particles containing chimeric viral proteins and compounds thereof
HK1202809A1 (en) Mammalian fetal pulmonary cells and therapeutic use of same
SG10201608341XA (en) Cd40l expressing mammalian cells and their use
IL226666B (en) Methods of generating corneal cells and cell populations comprising same
IL235323A0 (en) Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene
EP2477650B8 (en) Virus like particles comprising target proteins fused to plant viral coat proteins
BR112013018845A2 (pt) expressão de glicoproteínas de fusão viral solúveis em células de mamífero
IL223665B (en) Human antibodies to human cytomegalovirus gb (cmv) protein
EP2616073A4 (en) INHIBITORS OF IMMERSION OF VIRUSES IN MAMMALIAN HOST CELLS
IL200187A0 (en) Recombinant antigens of human cytomegalovirus (hcmv)
TWI842079B (zh) 人類rpe細胞之醫藥組合物及其用途